Emergent Biosolutions Inc (N:EBS)

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEC
Company Contact
Address: 400 Professional Dr Ste 400
Tel: 1-240-6313280
Website: https://emergentbiosolutions.com
IR: See website
Key People
Fuad El-Hibri
Executive Chairman of the Board
Robert G. Kramer
President, Chief Executive Officer, Director
Richard S. Lindahl
Chief Financial Officer, Executive Vice President, Treasurer
Katherine Strei
Executive Vice President, Human Resources and Communications, Chief Human Resources Officer
Atul Saran
Executive Vice President, Corporate Development, General Counsel and Corporate Secretary
Adam Havey
Executive Vice President - Business Operations
Sean Kirk
Executive Vice President, Manufacturing and Technical Operations
Business Overview
Emergent BioSolutions Inc. is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs). The PHTs operates through two categories: Chemical, Biological, Radiological and Nuclear, as well as explosive-related threats and emerging infectious diseases. It operates through four business units: Vaccines and Anti-infectives; Antibody Therapeutics; Devices, and Contract Manufacturing. Vaccines and Anti-infectives business unit consists of BioThrax, which is for the general use prophylaxis and post-exposure prophylaxis of anthrax disease. Devices business unit consists of marketed products, such as Reactive Skin Decontamination Lotion Kit (RSDL) and Trobigard (atropine sulfate, obidoxime chloride).
Financial Overview
For the six months ended 30 June 2020, Emergent Biosolutions Inc revenues increased 35% to $587.2M. Net income totaled $80.2M vs. loss of $35.5M. Revenues reflect U.S.Government segment increase of 66% to $375.4M, Non-U.S Government segment increase of 2% to $211.8M. Net Income reflects Research and development decrease of 18% to $90.6M (expense), Interest expense decrease of 21% to $15M (expense).
Employees: 1,834 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $5,842M as of Jun 30, 2020
Annual revenue (TTM): $1,259M as of Jun 30, 2020
EBITDA (TTM): $375.20M as of Jun 30, 2020
Net annual income (TTM): $170.30M as of Jun 30, 2020
Free cash flow (TTM): $184.00M as of Jun 30, 2020
Net Debt Last Fiscal Year: $518.40M as of Jun 30, 2020
Shares outstanding: 52,924,889 as of Jul 24, 2020
Index Membership: S&P 400 Mid Cap
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.